Full Text Journal Articles by
Author Silvio Danese

Advertisement

Find full text journal articles






Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Daniele Piovani, Claudia Pansieri, Soumya R R Kotha, Amanda C Piazza, Celia-Louise Comberg, Laurent Peyrin-Biroulet, Silvio Danese, Stefanos Bonovas,

<h4>Background and aims</h4>The association between smoking and inflammatory bowel disease [IBD] relies on old meta-analyses including exclusively non-Jewish White populations. Uncertainty persists regarding the role of smoking in other ethnicities.<h4>Methods</h4>We systematically searched Medline/PubMed, Embase, and Scopus for studies examining tobacco smoking and the risk of developing IBD, ie, Crohn's disease ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(10):1658-1678]

Cited: 0 times

View full text PDF listing >>



Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis.

David T Rubin, Irene Modesto, Séverine Vermeire, Silvio Danese, Siew C Ng, Kenneth K Kwok, Nana Koram, Thomas V Jones,

<h4>Background</h4>Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Post-marketing surveillance (PMS) is an important part of monitoring adverse events (AEs).<h4>Aims</h4>To report an analysis of PMS case safety reports for tofacitinib in patients with UC METHODS: Worldwide tofacitinib PMS reports received in the Pfizer safety ... Read more >>

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Bispecific antibodies for the treatment in inflammatory bowel disease: an avenue worth exploring?

Bénédicte Caron, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet,

Expert Opin Biol Ther (Expert opinion on biological therapy)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.

David A Schwartz, Laurent Peyrin-Biroulet, Karen Lasch, Shashi Adsul, Silvio Danese,

<h4>Background & aims</h4>Fistulizing Crohn's disease (CD) is challenging to treat. We report results from ENTERPRISE, a randomized, double-blind, phase 4 trial, evaluating 2 vedolizumab intravenous dosing regimens in patients with fistulizing CD.<h4>Methods</h4>Patients with moderately to severely active CD and 1-3 active perianal fistulae (identified on magnetic resonance imaging [MRI]), received ... Read more >>

Clin Gastroenterol Hepatol (Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis.

Ferdinando D'Amico, Lucas Guillo, Cedric Baumann, Silvio Danese, Laurent Peyrin-Biroulet,

<h4>Background and aims</h4>Histological healing might be the ultimate therapeutic goal in ulcerative colitis [UC]. Our aim was to investigate the association between histological disease activity as measured by a validated index and long-term outcomes in patients with UC.<h4>Methods</h4>An observational retrospective cohort study was conducted at the Nancy University Hospital between ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(10):1631-1640]

Cited: 1 time

View full text PDF listing >>



The Multiple Faces of Integrin-ECM Interactions in Inflammatory Bowel Disease.

Valentina Garlatti, Sara Lovisa, Silvio Danese, Stefania Vetrano,

Inflammatory Bowel Disease (IBD) comprises a series of chronic and relapsing intestinal diseases, with Crohn's disease and ulcerative colitis being the most common. The abundant and uncontrolled deposition of extracellular matrix, namely fibrosis, is one of the major hallmarks of IBD and is responsible for the progressive narrowing and closure ... Read more >>

Int J Mol Sci (International journal of molecular sciences)
[2021, 22(19):]

Cited: 0 times

View full text PDF listing >>



Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.

Lucie Weislinger, Lucas Guillo, Ferdinando D'Amico, Silvio Danese, Hamza Achit, Carole Ayav, Francis Guillemin, Laurent Peyrin-Biroulet, Luc Frimat,

<h4>Background and aim</h4>5-Aminosalicylic acid (5-ASA) nephrotoxicity is a rare and idiosyncratic condition in patients with inflammatory bowel disease (IBD), which may lead to end-stage kidney failure. Kidney function monitoring is recommended in clinical practice to prevent this complication. However, no data is available regarding the knowledge and adherence of patients ... Read more >>

Eur J Gastroenterol Hepatol (European journal of gastroenterology & hepatology)
[2021, 33(9):1148-1152]

Cited: 0 times

View full text PDF listing >>



PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.

William Sandborn, Larry C Mattheakis, Nishit B Modi, David Pugatch, Brian Bressler, Scott Lee, Raj Bhandari, Bittoo Kanwar, Richard Shames, Geert D'Haens, Stefan Schreiber, Silvio Danese, Brian Feagan, Rish K Pai, David Y Liu, Suneel Gupta,

<h4>Background & aims</h4>Oral therapies targeting the integrin α4β7 may offer unique advantages for the treatment of inflammatory bowel disease. We characterized the oral α4β7 antagonist peptide PTG-100 in preclinical models and established safety, pharmacokinetic/pharmacodynamic relationships, and efficacy in a phase 2a trial in patients with ulcerative colitis (UC).<h4>Methods</h4>In vitro studies measured ... Read more >>

Gastroenterology (Gastroenterology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents.

Virginia Solitano, Tommaso Lorenzo Parigi, Elisa Ragaini, Silvio Danese,

<h4>Introduction</h4>Despite huge and increasing developments in the treatment of inflammatory bowel disease (IBD), a significant percentage of patients with Crohn's disease (CD) and ulcerative colitis (UC) is still in need of an effective and safe therapeutic option. Tackling the trafficking of leukocytes specifically within or directed to the inflamed gut ... Read more >>

Expert Opin Investig Drugs (Expert opinion on investigational drugs)
[2021, :1-10]

Cited: 0 times

View full text PDF listing >>



Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.

William J Sandborn, Brian G Feagan, Geert D'Haens, Douglas C Wolf, Igor Jovanovic, Stephen B Hanauer, Subrata Ghosh, AnnKatrin Petersen, Steven Y Hua, Ji Hwan Lee, Lorna Charles, Denesh Chitkara, Keith Usiskin, Jean-Frederic Colombel, Loren Laine, Silvio Danese, ,

<h4>Background</h4>Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease.<h4>Methods</h4>We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of ozanimod as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. In the 10-week induction period, patients in cohort 1 ... Read more >>

N Engl J Med (The New England journal of medicine)
[2021, 385(14):1280-1291]

Cited: 0 times

View full text PDF listing >>



Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis.

Mina Hassan-Zahraee, Zhan Ye, Li Xi, Mary Lynn Baniecki, Xingpeng Li, Craig L Hyde, Jenny Zhang, Nancy Raha, Fridrik Karlsson, Jie Quan, Daniel Ziemek, Srividya Neelakantan, Christopher Lepsy, Jessica R Allegretti, Jacek Romatowski, Ellen J Scherl, Maria Klopocka, Silvio Danese, Deepa E Chandra, Uwe Schoenbeck, Michael S Vincent, Randy Longman, Kenneth E Hung,

<h4>Background</h4>The first-in-class treatment PF-06480605 targets the tumor necrosis factor-like ligand 1A (TL1A) molecule in humans. Results from the phase 2a TUSCANY trial highlighted the safety and efficacy of PF-06480605 in ulcerative colitis. Preclinical and in vitro models have identified a role for TL1A in both innate and adaptive immune responses, ... Read more >>

Inflamm Bowel Dis (Inflammatory bowel diseases)
[2021, :]

Cited: 0 times

View full text PDF listing >>



International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Pablo A Olivera, Stephane Zuily, Paulo G Kotze, Veronique Regnault, Sameer Al Awadhi, Peter Bossuyt, Richard B Gearry, Subrata Ghosh, Taku Kobayashi, Patrick Lacolley, Edouard Louis, Fernando Magro, Siew C Ng, Alfredo Papa, Tim Raine, Fabio V Teixeira, David T Rubin, Silvio Danese, Laurent Peyrin-Biroulet,

Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial ... Read more >>

Nat Rev Gastroenterol Hepatol (Nature reviews. Gastroenterology & hepatology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.

Séverine Vermeire, Geert D'Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V Loftus, Siddharth Bhatia, Christian Agboton, Maria Rosario, Chunlin Chen, Wenwen Zhang, Krisztina Kisfalvi, William J Sandborn,

<h4>Background and aims</h4>Report results from VISIBLE 2, a randomised, double-blind, placebo-controlled phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn's disease [CD].<h4>Methods</h4>Following open-label vedolizumab 300 mg intravenous induction therapy at Weeks 0 and 2, Week 6 clinical responders (≥70-point ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a Novel UC-Ultrasound Index.

Mariangela Allocca, Stefanos Bonovas, Silvio Danese,

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(8):1405-1406]

Cited: 0 times

View full text PDF listing >>



Adalimumab biosimilar in inflammatory bowel disease.

Gionata Fiorino, Mariangela Allocca, Silvio Danese,

Lancet Gastroenterol Hepatol (The lancet. Gastroenterology & hepatology)
[2021, 6(10):775-776]

Cited: 0 times

View full text PDF listing >>



Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials.

Bénédicte Caron, Ferdinando D'Amico, Silvio Danese, Laurent Peyrin-Biroulet,

Randomized clinical trials are the gold standard for new drugs development. Clinical trials became increasingly complex, in particular in the field of inflammatory bowel diseases. For this reason, a new study design called "cluster randomized trial" has been introduced. Cluster randomized trials randomly assign groups of individuals within a population ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



A multidisciplinary approach to rectal cancer treatment in ulcerative colitis results in high rate of restorative minimally invasive surgery.

Michele Carvello, Vittoria Bellato, Annalisa Maroli, Ailsa Hart, Silvio Danese, Janindra Warusavitarne, Antonino Spinelli,

<h4>Background and aims</h4>Few recent studies focus on the treatment of rectal cancer in patients with ulcerative colitis. We report treatment options and results for this subset of patients with a multimodal approach at two European referral centers.<h4>Methods</h4>Ulcerative colitis patients diagnosed with rectal cancer arising at less than 15 cm from the ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Endpoints for Perianal Crohn's Disease Trials: Past, Present and Future.

Bénédicte Caron, Ferdinando D'Amico, Silvio Danese, Laurent Peyrin-Biroulet,

<h4>Background and aims</h4>Since the 1980s, many studies have evaluated the efficacy of therapies to improve the outcomes of patients with perianal Crohn's disease. We performed a systematic review to describe the evolution of endpoints in perianal fistulizing Crohn's disease. Efficacy outcomes, definitions and measurement tools were assessed.<h4>Methods</h4>Electronic databases were searched ... Read more >>

J Crohns Colitis (Journal of Crohn's & colitis)
[2021, 15(8):1387-1398]

Cited: 0 times

View full text PDF listing >>



Therapeutic Response to Adalimumab in a Case of Steroid-Dependent Segmental Colitis Associated With Diverticulosis.

Antonio Tursi, Rosanna Nenna, Silvio Danese,

Am J Gastroenterol (The American journal of gastroenterology)
[2021, 116(8):1760-1761]

Cited: 0 times

View full text PDF listing >>



Intestinal ischemic manifestations of SARS-CoV-2: Results from the ABDOCOVID multicentre study.

Lorenzo Norsa, Pietro Andrea Bonaffini, Maja Caldato, Cristiana Bonifacio, Aurelio Sonzogni, Amedeo Indriolo, Clarissa Valle, Federica Furfaro, Alice Bonanomi, Paolo Niccolò Franco, Mauro Gori, Veronica Smania, Lucia Scaramella, Laura Forzenigo, Maurizio Vecchi, Monica Solbiati, Giorgio Costantino, Silvio Danese, Lorenzo D'Antiga, Sandro Sironi, Luca Elli,

<h4>Background</h4>Intestinal ischemia has been described in case reports of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (coronavirus disease 19, COVID-19).<h4>Aim</h4>To define the clinical and histological, characteristics, as well as the outcome of ischemic gastrointestinal manifestations of SARS-CoV-2 infection.<h4>Methods</h4>A structured retrospective collection was promoted among three tertiary referral ... Read more >>

World J Gastroenterol (World journal of gastroenterology)
[2021, 27(32):5448-5459]

Cited: 0 times

View full text PDF listing >>



The new frontier: Certifying quality standards in the inflammatory bowel disease care.

Gionata Fiorino, Silvio Danese,

United European Gastroenterol J (United European gastroenterology journal)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Bowel Ultrasound in Inflammatory Bowel Disease: How Far in the Grayscale?

Federica Furfaro, Arianna Dal Buono, Mariangela Allocca, Ferdinando D'Amico, Alessandra Zilli, Roberto Gabbiadini, Silvio Danese,

Bowel ultrasound (BUS) is a non-invasive and accurate technique for assessing activity, extension of disease, and complications in inflammatory bowel diseases. The main advantages of BUS are its safety, reproducibility, and low costs. Ancillary technologies of BUS (i.e., color Doppler and wave elastography) could broaden the diagnostic power of BUS, ... Read more >>

Life (Basel) (Life (Basel, Switzerland))
[2021, 11(7):]

Cited: 0 times

View full text PDF listing >>



Patients' perceptions of surgery for inflammatory bowel disease.

Antonino Spinelli, Michele Carvello, Michel Adamina, Yves Panis, Janindra Warusavitarne, Hagit Tulchinsky, Willem A Bemelman, Paulo Gustavo Kotze, Andre D'Hoore, Lucie Lastikova, Silvio Danese, Laurent Peyrin-Biroulet, Luisa Avedano, Francesco Pagnini,

<h4>Aim</h4>Surgery is indicated in selected patients with inflammatory bowel disease (IBD). However, due to a negative perception, surgery may be delayed, leading to possible unfavourable outcomes. The aim of this work was to investigate patients' perceptions of surgery and the impact on reported outcomes.<h4>Method</h4>An international multilingual online survey was used ... Read more >>

Colorectal Dis (Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland)
[2021, :]

Cited: 0 times

View full text PDF listing >>



IBD goes home: from telemedicine to self-administered advanced therapies.

Virginia Solitano, Ludovico Alfarone, Ferdinando D'Amico, Laurent Peyrin-Biroulet, Silvio Danese,

<b>Introduction</b>: Major challenges have been posed by the coronavirus disease 2019 pandemic in the routine management of patients with inflammatory bowel disease (IBD). The need for constant monitoring of diseases activity and prompt adjustment of therapy have been balanced with the risk of contagion related to face-to-face consultations. Therefore, digital ... Read more >>

Expert Opin Biol Ther (Expert opinion on biological therapy)
[2021, :1-13]

Cited: 0 times

View full text PDF listing >>



Italian Consensus Statement for Promoting Psycho-Social Wellbeing and Engagement in the Care of Inflammatory Bowel Disease Patients

Guendalina Graffigna, Caterina Bosio, Francesco Pagnini, Eleonora Volpato, Enrica Previtali, Salvatore Leone, Ferdinando D’Amico, Alessandro Armuzzi, Silvio Danese,

Inflammatory bowel diseases (IBD) are remitting and relapsing diseases that mainly interest the gastrointestinal tract. This is associated with a condition of psycho-social discomfort that prevents the affected person from living normally and deeply compromises the quality of life in terms of personal, work, and interpersonal well-being. Management of IBD ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

1.6418 s